Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment

Journal of Immunological Methods

Volumn 280, Issue 1-2, 2003, Pages 1-11

  Mocellin, Simone ^a   Provenzano, Maurizio ^a   Rossi, Carlo R ^a   Pilati, Pierluigi ^a   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cytokine; Quantitative PCR; TNF ; Tumor microenvironment

Indexed keywords

CANCER GROWTH FACTOR; CD14 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROTEIN; PROTEIN SUBUNIT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FUNCTIONAL ASSESSMENT; GENE AMPLIFICATION; HELPER CELL; HOUSEKEEPING GENE; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LEUKOCYTE; LIMB PERFUSION; MACROPHAGE; MARKER GENE; MICROENVIRONMENT; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; SOFT TISSUE SARCOMA; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR; TUMOR BIOPSY;

EID: 0142043427     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00274-6     Document Type: Article

References (41)

1. Alexander H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16:1998;1479-1489.
2. Aruga A., Aruga E., Tanigawa K., Bishop D.K., Sondak V.K., Chang A.E. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159:1997;664-673.
3. Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P.et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer. 77:1998;7-12.
4. Beaty R.M., Rulli K., Bost K.L., Pantginis J., Lenz J., Levy L.S. High levels of IL-4 and IL-10 mRNA and low levels of IL-2, IL-9 and IFN- gamma mRNA in MuLV-induced lymphomas. Virology. 261:1999;253-262.
5. Bellone G., Turletti A., Artusio E., Mareschi K., Carbone A.et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155:1999;537-547.
6. Blankenstein T., Qin Z.H., Uberla K., Muller W., Rosen H.et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 173:1991;1047-1052.
7. Bohlen H., Kessler M., Sextro M., Diehl V., Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann. Hematol. 79:2000;110-113.
8. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21:1999;33-37.
9. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72:1975;3666-3670.
10. Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Pospisil M.et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:1991;869-879.
11. Clerici M., Shearer G.M., Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J. Natl. Cancer Inst. 90:1998;261-263.
12. Conrad C.T., Ernst N.R., Dummer W., Brocker E.B., Becker J.C. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J. Exp. Clin. Cancer Res. 18:1999;225-232.
13. Cox G.W., Melillo G., Chattopadhyay U., Mullet D., Fertel R.H., Varesio L. Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol. 149:1992;3290-3296.
14. de Wilt J.H., ten Hagen T.L., de Boeck G., van Tiel S.T., de Bruijn E.A., Eggermont A.M. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer. 82:2000;1000-1003.
15. Eggermont A.M., Schraffordt Koops H., Klausner J.M., Kroon B.B., Schlag P.M.et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 224:1996;756-764. discussion 764-5.
16. Filella X., Alcover J., Zarco M.A., Beardo P., Molina R., Ballesta A.M. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate. 44:2000;271-274.
17. Gnant M.F., Berger A.C., Huang J., Puhlmann M., Wu P.C.et al. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res. 59:1999;4668-4674.
18. Hsieh C.L., Chen D.S., Hwang L.H. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. 11:2000;681-692.
19. Hu H.M., Urba W.J., Fox B.A. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:1998;3033-3041.
20. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:1995;3847-3853.
21. Kammula U.S., Marincola F.M., Rosenberg S.A. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92:2000;1336-1344.
22. Lappin M.B., Campbell J.D. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev. 14:2000;228-239.
23. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 10:1998;573-580.
24. Lienard D., Ewalenko P., Delmotte J.J., Renard N., Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10:1992;52-60.
25. Lowes M.A., Bishop G.A., Crotty K., Barnetson R.S., Halliday G.M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. 108:1997;914-919.
26. Lucey D.R., Clerici M., Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9:1996;532-562.
27. Mocellin S., Fetsch P., Abati A., Phan G.Q., Wang E.et al. Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. J. Immunother. 24:2001;447-458.
28. Mocellin S., Ohnmacht G.A., Wang E., Marincola F.M. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer. 93:2001;236-242.
29. Mocellin S., Wang E., Marincola F.M. Cytokines and immune response in the tumor microenvironment. J. Immunother. 24:2001;392-407.
30. Nooijen P.T., Eggermont A.M., Schalkwijk L., Henzen-Logmans S., de Waal R.M., Ruiter D.J. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 58:1998;4880-4887.
31. Ohnmacht G.A., Wang E., Mocellin S., Abati A., Filie A.et al. Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:2001;1809-1820.
32. Ostensen M.E., Thiele D.L., Lipsky P.E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J. Immunol. 138:1987;4185-4191.
33. Panelli M.C., Wang E., Monsurro V., Marincola F.M. The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin. Biol. Ther. 2:2002;537-544.
34. Panelli M.C., Wang E., Phan G., Puhlmann M., Miller L.et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 3:2002;1-17. (RESEARCH0035).
35. Rossi C.R., Vecchiato A., Foletto M., Nitti D., Ninfo V.et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer. 73:1994;2140-2146.
36. Rossi C.R., Foletto M., Di Filippo F., Vaglini M., Anza M.et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer. 86:1999;1742-1749.
37. van der Veen A.H., de Wilt J.H., Eggermont A.M., van Tiel S.T., Seynhaeve A.L., ten Hagen T.L. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer. 82:2000;973-980.
38. Wang E., Marincola F.M. A natural history of melanoma: serial gene expression analysis. Immunol. Today. 21:2000;619-623.
39. Wang E., Marincola F.M. cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J. 7:2001;16-24.
40. Wang E., Miller L.D., Ohnmacht G.A., Liu E.T., Marincola F.M. High-fidelity mRNA amplification for gene profiling. Nat. Biotechnol. 18:2000;457-459.
41. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Perez-Diez A.et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:2002;3581-3586.